Compare Achillion Pharmaceuticals vs Crux Biomedical
Customers evaluate the quality of Achillion Pharmaceuticals's products using the following success metrics.
Overview
Achillion Pharmaceuticals is 26 yrs old and is based in United States.
Achillion is a biopharmaceutical company engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. On January 28th, 2020, Achillion Pharmaceuticals was acquired by Alexion million.
Crux Biomedical is 20 yrs old and is based in United States.
Crux Biomedical is focused on developing improved therapies for the human vasculature. The company's inferior vena cava filters (IVCF) are designed to prevent an often fatal condition known as pulmonary embolism (PE). PE is caused by migration of a large blood clot arising from deep veins of the legs, a condition known as deep vein thrombosis (DVT). In December 2012, Crux Biomedical was acquired by Volcano Corporation. The valuation of Crux Biomedical was $36 million. Other terms of the deal were not released.
Demo Video
Leadership
Stephen K Carter (Founder)
Chris Schaffer (Chief Financial Officer)
Investors
Alexion, AstraZeneca Rare Disease, Pappas Ventures
Volcano Corporation, Alloy Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Achillion Pharmaceuticals has not claimed their profile.
Work for Achillion Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Achillion Pharmaceuticals?
Claim your profile now.
Information not available because Crux Biomedical has not claimed their profile.
Work for Crux Biomedical? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Crux Biomedical?
Claim your profile now.